Ignite Creation Date:
2024-07-17 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06490328
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-13
Brief Title:
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Sponsor:
Dongkook Pharmaceutical Co Ltd
Organization:
Dongkook Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase 3 Multi-center Single-group Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase 3 multi-center single-group open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer
Detailed Description:
This study is conducted to confirm the pharmacodynamic effects efficacy and safety of DKF-MA102 in prostate cancer patients by measuring the changes in serum testosterone levels
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None